1
|
Debin M, Launay T, Rossignol L, Ait El Belghiti F, Brisse S, Guillot S, Guiso N, Levy-Bruhl D, Merdrignac L, Toubiana J, Blanchon T, Hanslik T. Pertussis surveillance results from a French general practitioner network, France, 2017 to 2020. Euro Surveill 2022; 27:2100515. [PMID: 35485270 PMCID: PMC9052767 DOI: 10.2807/1560-7917.es.2022.27.17.2100515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Accepted: 02/04/2022] [Indexed: 12/05/2022] Open
Abstract
IntroductionIn France, three complementary surveillance networks involving hospitals and paediatrician practices currently allow pertussis surveillance among infants (<1 year old) and children (1-12 years old). Data on incidences among adolescents (13-17 years old) and adults (≥ 18 years) are scarce. In 2017, a sentinel surveillance system called Sentinelles network, was implemented among general practitioners (GPs).AimThe purpose of Sentinelles network is to assess pertussis incidence, monitor the cases' age distribution and evaluate the impact of the country's vaccination policy. We present the results from the first 4 years of this surveillance.MethodsGPs of the French Sentinelles network reported weekly numbers of epidemiologically or laboratory-confirmed cases and their characteristics.ResultsA total of 132 cases were reported over 2017-2020. Estimated national incidence rates per 100,000 inhabitants were 17 (95% confidence interval (CI): 12-22) in 2017, 10 (95% CI: 6-14) in 2018, 15 (95% CI: 10-20) in 2019 and three (95% CI: 1-5) in 2020. The incidence rate was significantly lower in 2020 than in 2017-2019. Women were significantly more affected than men (83/132; 63% of women, p = 0.004); 66% (87/132) of cases were aged 15 years or over (median age: 31.5 years; range: 2 months-87 years). Among 37 vaccinated cases with data, 33 had received the recommended number of doses for their age.ConclusionsThese results concur with incidences reported in other European countries, and with studies showing that the incidences of several respiratory diseases decreased in 2020 during the COVID-19 pandemic. The results also suggest a shift of morbidity towards older age groups, and a rapid waning of immunity after vaccination, justifying to continue this surveillance.
Collapse
Affiliation(s)
- Marion Debin
- Sorbonne Université, INSERM, Institut Pierre-Louis d'Épidémiologie et de santé publique, Paris, France
| | - Titouan Launay
- Sorbonne Université, INSERM, Institut Pierre-Louis d'Épidémiologie et de santé publique, Paris, France
| | - Louise Rossignol
- Sorbonne Université, INSERM, Institut Pierre-Louis d'Épidémiologie et de santé publique, Paris, France
- Université Paris Cité, Département de médecine générale, Paris, France
| | | | - Sylvain Brisse
- Institut Pasteur, National Reference Center for Whooping Cough and other Bordetella Infections, Paris, France
- Institut Pasteur, Université Paris Cité, Biodiversity and Epidemiology of Bacterial Pathogens Unit, Paris, France
| | - Sophie Guillot
- Institut Pasteur, National Reference Center for Whooping Cough and other Bordetella Infections, Paris, France
- Institut Pasteur, Université Paris Cité, Biodiversity and Epidemiology of Bacterial Pathogens Unit, Paris, France
| | | | - Daniel Levy-Bruhl
- Santé publique France, Département des maladies infectieuses, Saint-Maurice, France
| | - Lore Merdrignac
- Sorbonne Université, INSERM, Institut Pierre-Louis d'Épidémiologie et de santé publique, Paris, France
- Epiconcept, Paris, France
| | - Julie Toubiana
- Institut Pasteur, National Reference Center for Whooping Cough and other Bordetella Infections, Paris, France
- Institut Pasteur, Université Paris Cité, Biodiversity and Epidemiology of Bacterial Pathogens Unit, Paris, France
- Université Paris Cité, Service de Pédiatrie Générale et Maladies Infectieuses, Hôpital Necker -Enfants malades, Assistance Publique-Hôpitaux de Paris, AP-HP, Paris, France
| | - Thierry Blanchon
- Sorbonne Université, INSERM, Institut Pierre-Louis d'Épidémiologie et de santé publique, Paris, France
| | - Thomas Hanslik
- Sorbonne Université, INSERM, Institut Pierre-Louis d'Épidémiologie et de santé publique, Paris, France
- Assistance Publique-Hôpitaux de Paris, AP-HP, Hôpital Ambroise Paré, Service de Médecine Interne, Boulogne Billancourt, Paris, France
- Université Versailles-Saint-Quentin-en-Yvelines, UVSQ, UFR des sciences de la santé Simone-Veil, Versailles, France
| |
Collapse
|
2
|
Vancraeynest E, Cattoir L, Van Vaerenbergh K, De Beenhouwer H, Vankeerberghen A, Boel A. Bacteremia and complicated parapneumonic effusion caused by Bordetella holmesii in an elderly patient. Acta Clin Belg 2021; 76:307-309. [PMID: 32009598 DOI: 10.1080/17843286.2020.1724448] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
We describe a case of bacteremia and a complicated parapneumonic effusion caused by Bordetella holmesii, in an elderly patient with underlying chronic hepatitis C infection.
Collapse
Affiliation(s)
| | - Lien Cattoir
- Laboratory of Clinical Microbiology, Aalst, Belgium
| | | | | | | | - An Boel
- Laboratory of Clinical Microbiology, Aalst, Belgium
| |
Collapse
|
3
|
Bordetella holmesii Bacteremia and Cellulitis in an Immunocompetent Patient. INFECTIOUS DISEASES IN CLINICAL PRACTICE 2020. [DOI: 10.1097/ipc.0000000000000863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
4
|
Spondylodiscitis caused by Bordetella holmesii, a misrecognized pathogen emerging in invasive infections. Int J Infect Dis 2018; 75:95-97. [DOI: 10.1016/j.ijid.2018.07.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Revised: 07/12/2018] [Accepted: 07/13/2018] [Indexed: 11/23/2022] Open
|
5
|
Abstract
Since the first description of Bordetella holmesii in 1995, almost 100 publications have contributed to the increasing knowledge of this emerging bacterium. Although first reported to induce bacteremia mainly in immunocompromised patients, it has also been isolated in healthy persons and has shown the capacity to induce pertussis-like symptoms and other clinical entities, such as meningitis, arthritis, or endocarditis. Respiratory diseases are generally less severe than those induced by Bordetella pertussis. However, B. holmesii was found to have a higher capacity of invasiveness given the various infection sites in which it was isolated. The diagnosis is difficult, particularly as it is a slow-growing organism but also because respiratory infections are systematically misdiagnosed as B. pertussis. Treatment is delicate, as its susceptibility to macrolides (prescribed in respiratory infections) and ceftriaxone (used in invasive disease) is challenged. Regarding prevention, there is no consensus on prophylactic treatment following index cases and no vaccine is available. Epidemiological data are also sparse, with few prevalence studies available. In this chapter, we provide an overview of the current state of knowledge on B. holmesii.
Collapse
|
6
|
Bouchez V, AlBitar-Nehmé S, Novikov A, Guiso N, Caroff M. Bordetella holmesii: Lipid A Structures and Corresponding Genomic Sequences Comparison in Three Clinical Isolates and the Reference Strain ATCC 51541. Int J Mol Sci 2017; 18:ijms18051080. [PMID: 28524084 PMCID: PMC5454989 DOI: 10.3390/ijms18051080] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2017] [Revised: 05/05/2017] [Accepted: 05/11/2017] [Indexed: 11/16/2022] Open
Abstract
Bordetella holmesii can cause invasive infections but can also be isolated from the respiratory tract of patients with whooping-cough like symptoms. For the first time, we describe the lipid A structure of B. holmesii reference strain ATCC 51541 (alias NCTC12912 or CIP104394) and those of three French B. holmesii clinical isolates originating from blood (Bho1) or from respiratory samples (FR4020 and FR4101). They were investigated using chemical analyses, gas chromatography–mass spectrometry (GC–MS), and matrix-assisted laser desorption ionization–mass spectrometry (MALDI–MS). The analyses revealed a common bisphosphorylated β-(1→6)-linked d-glucosamine disaccharide with hydroxytetradecanoic acid in amide linkages. Similar to B. avium, B. hinzii and B. trematum lipids A, the hydroxytetradecanoic acid at the C-2′ position are carrying in secondary linkage a 2-hydroxytetradecanoic acid residue resulting of post-traductional biosynthesis modifications. The three clinical isolates displayed characteristic structural traits compared to the ATCC 51541 reference strain: the lipid A phosphate groups are more or less modified with glucosamine in the isolates and reference strain, but the presence of 10:0(3-OH) is only observed in the isolates. This trait was only described in B. pertussis and B. parapertussis strains, as well as in B. petrii isolates by the past. The genetic bases for most of the key structural elements of lipid A were analyzed and supported the structural data.
Collapse
Affiliation(s)
- Valérie Bouchez
- Institut Pasteur, Unité de Prévention et Thérapies Moléculaires des Maladies Humaines, 25 rue du Dr Roux, 75724 Paris, France.
| | - Sami AlBitar-Nehmé
- Institute for integrative Biology of the Cell (I2BC), Commissariat à l'Energie Atomique (CEA), Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay, 91405 Orsay, France.
| | - Alexey Novikov
- LPS-BioSciences, I2BC, Bâtiment 409, Université de Paris-Sud, 91405 Orsay, France.
| | - Nicole Guiso
- Institut Pasteur, Unité de Prévention et Thérapies Moléculaires des Maladies Humaines, 25 rue du Dr Roux, 75724 Paris, France.
| | - Martine Caroff
- Institute for integrative Biology of the Cell (I2BC), Commissariat à l'Energie Atomique (CEA), Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay, 91405 Orsay, France.
- LPS-BioSciences, I2BC, Bâtiment 409, Université de Paris-Sud, 91405 Orsay, France.
| |
Collapse
|
7
|
Pittet LF, Posfay-Barbe KM. Bordetella holmesiiinfection: current knowledge and a vision for future research. Expert Rev Anti Infect Ther 2015; 13:965-71. [DOI: 10.1586/14787210.2015.1056161] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
8
|
[Haut Conseil de la santé publique (HCSP). Management of single or multiple pertussis cases]. Rev Mal Respir 2015; 32:639-56. [PMID: 26054984 DOI: 10.1016/j.rmr.2014.12.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
-
- 14, avenue Duquesne, 75350 Paris 07 SP, France. http://www.hcsp.fr
| |
Collapse
|
9
|
Almuzara M, Barberis C, Traglia G, Sly G, Procopio A, Vilches V, Ramirez MS, Famiglietti A, Vay C. Isolation of Bordetella species from unusual infection sites. JMM Case Rep 2015. [DOI: 10.1099/jmmcr.0.000029] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- Marisa Almuzara
- Laboratorio de Bacteriología. Hospital Interzonal de Agudos Eva Perón, Provincia de Buenos Aires, Argentina
- Laboratorio de Bacteriología, Departamento de Bioquímica Clínica, Hospital de Clínicas José de San Martín, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| | - Claudia Barberis
- Laboratorio de Bacteriología, Departamento de Bioquímica Clínica, Hospital de Clínicas José de San Martín, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| | - Germán Traglia
- Instituto de Microbiología y Parasitología Médica (IMPaM, UBA‐CONICET), Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Gabriela Sly
- Laboratorio de Bacteriología. Hospital Interzonal de Agudos Eva Perón, Provincia de Buenos Aires, Argentina
| | - Adriana Procopio
- Laboratorio de Bacteriología, Hospital de Niños Ricardo Gutierrez, Ciudad Autónoma de Buenos Aires, Argentina
| | - Viviana Vilches
- Laboratorio de Microbiología, Hospital Universitario Austral, Provincia de Buenos Aires, Argentina
| | - Maria Soledad Ramirez
- Center for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, Fullerton, CA, USA
- Instituto de Microbiología y Parasitología Médica (IMPaM, UBA‐CONICET), Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Angela Famiglietti
- Laboratorio de Bacteriología, Departamento de Bioquímica Clínica, Hospital de Clínicas José de San Martín, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| | - Carlos Vay
- Laboratorio de Bacteriología, Departamento de Bioquímica Clínica, Hospital de Clínicas José de San Martín, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| |
Collapse
|
10
|
Abstract
Bordetella holmesii is a rare cause of invasive human disease. The fastidious and unusual nature of this organism makes routine isolation and identification challenging. We report two cases of B. holmesii bacteremia that were rapidly identified by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS) when standard techniques failed to provide speciation. There are no current standards for susceptibility testing or treatment recommendations. The rare occurrence and challenges in identifying this pathogen led us to perform a comprehensive review of the epidemiology, clinical presentations, and treatment options for this potentially invasive pathogen.
Collapse
|
11
|
Abstract
The Bordetella genus comprises nine species of which Bordetella pertussis and B. parapertussis are isolated from humans and are the most studied Bordetella species since they cause whooping cough. They both originate from B. bronchiseptica, which infects several mammals and immune compromised humans, but the intensive use of pertussis vaccines induced changes in B. pertussis and B. parapertussis populations. B. petrii and B. holmesii are other species of unknown reservoir and transmission pattern that have been described in humans. It is still unknown whether these species are pathogens for humans or only opportunistic bacteria but biological diagnosis has confirmed the presence of B. holmesii in human respiratory samples while B. petrii and the four other species have little implications for public health.
Collapse
Affiliation(s)
- Nicole Guiso
- Institut Pasteur, Unité de Prévention et Thérapies Moléculaires des Maladies Humaines, 25-28 rue du Dr Roux, F-75015 Paris, France
| | | |
Collapse
|
12
|
Pittet LF, Emonet S, Schrenzel J, Siegrist CA, Posfay-Barbe KM. Bordetella holmesii: an under-recognised Bordetella species. THE LANCET. INFECTIOUS DISEASES 2014; 14:510-9. [PMID: 24721229 DOI: 10.1016/s1473-3099(14)70021-0] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Bordetella holmesii, first described in 1995, is believed to cause both invasive infections (bacteraemia, meningitis, endocarditis, pericarditis, pneumonia, and arthritis) and pertussis-like symptoms. Infection with B holmesii is frequently misidentified as being with B pertussis, the cause of whooping cough, because routine diagnostic tests for pertussis are not species-specific. In this Review, we summarise knowledge about B holmesii diagnosis and treatment, and assess research needs. Although no fatal cases of B holmesii have been reported, associated invasive infections can cause substantial morbidities, even in previously healthy individuals. Antimicrobial treatment can be problematic because B holmesii's susceptibility to macrolides (used empirically to treat B pertussis) and third-generation cephalosporins (often used to treat invasive infections) is lower than would be expected. B holmesii's adaptation to human beings is continuing, and virulence might increase, causing the need for better diagnostic assays and epidemiological surveillance.
Collapse
Affiliation(s)
- Laure F Pittet
- Department of Paediatrics, Division of General Paediatrics, Children's Hospital, University Hospitals of Geneva, University of Geneva, Geneva, Switzerland
| | - Stéphane Emonet
- Department of Genetics and Laboratory Medicine, Department of Medical Specialties, University Hospitals of Geneva, University of Geneva, Geneva, Switzerland
| | - Jacques Schrenzel
- Department of Genetics and Laboratory Medicine, Department of Medical Specialties, University Hospitals of Geneva, University of Geneva, Geneva, Switzerland
| | - Claire-Anne Siegrist
- Department of Paediatrics, Division of General Paediatrics, Children's Hospital, University Hospitals of Geneva, University of Geneva, Geneva, Switzerland; Neonatal Immunology, Departments of Pathology-Immunology and Paediatrics, University of Geneva, Geneva, Switzerland
| | - Klara M Posfay-Barbe
- Department of Paediatrics, Division of General Paediatrics, Children's Hospital, University Hospitals of Geneva, University of Geneva, Geneva, Switzerland.
| |
Collapse
|